Amylyx Pharmaceuticals (AMLX) Shares Outstanding (2021 - 2026)

Amylyx Pharmaceuticals has reported Shares Outstanding (Entity) for 6 years, with the latest figure at $111.4 million in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 24.91% year-over-year to $111.4 million in Q2 2026; TTM through Jun 2026 was $111.4 million, a 24.91% increase from a year earlier, with the FY2025 full-year figure at $109.9 million, up 60.11% from the prior year.
• Shares Outstanding (Entity) was $111.4 million for Q2 2026 at Amylyx Pharmaceuticals, roughly flat from $111.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $111.4 million in Q2 2026, with the low at $57.9 million in Q1 2022.
• Average Shares Outstanding (Entity) over 5 years is $78.0 million, with a median of $68.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) surged 847.4% in 2022, then rose 1.08% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $66.5 million in 2022, then climbed by 1.8% to $67.7 million in 2023, then advanced by 1.36% to $68.6 million in 2024, then jumped by 60.11% to $109.9 million in 2025, then rose by 1.35% to $111.4 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $111.4 million (Q2 2026), $111.0 million (Q1 2026), and $109.9 million (Q4 2025), per Business Quant data.